Nuvectis Pharma heads into September with its short book quietly unwinding and the lending market loosening at the fastest pace of the year — a notable shift from the elevated positioning that defined August.
The clearest change this week is in the borrow market. Cost to borrow has more than halved over the past month, dropping to 1.37% from a July peak above 6%. That is the easiest borrow condition NVCT has seen since early summer, and availability has surged back above 100% — meaning there is now more than one share available to lend for every share currently borrowed. As recently as late July, availability was below 25%. The loosening is consistent with short covering: short interest fell 11% in a single session on September 1, pulling the overall short position to 6.3% of the free float from a recent peak near 7%. The ORTEX short score has also retreated, dropping to 64.4 from around 69 where it spent most of August. That pullback signals the short thesis is losing momentum, not gaining it. The ORTEX short score ranks in just the 13th percentile of the universe — low enough to suggest the bears are not in control here.
Options positioning reinforces the bullish lean. The put/call ratio is running at 0.040, well below its 20-day average of 0.075 — and near the bottom of its 52-week range. The z-score of -1.2 confirms call demand is dominant, though less extreme than the -2.5 reading flagged in last week's note. The sharp drop in the PCR that coincided with NVCT's move through $25 in mid-August has moderated, but the directional tilt remains: options traders are still leaning long rather than hedging. The contrast with the short book is the week's defining tension — as shorts retreat, options buyers have not given back their conviction.
The Street aligns with that lean. All four covering analysts carry buy ratings, with a mean price target of $35.40 against the current $23.06 — implying roughly 54% upside to consensus. Cantor Fitzgerald initiated coverage with an Overweight rating on August 24, the most recent action from a named firm. Prior to that, Roth Capital raised its target to $33 in early July and HC Wainwright lifted to $39 in late June — both moves reflecting the sharp pipeline re-rating the stock has undergone since spring. The bull case rests on NXP900's licensing deal and Phase 1b data potential, plus NXP100 and NXP200 IND timelines. Bears point to the company's dependence on in-licensed assets, dilutive financing risk, and limited efficacy signals in early trials — a standard micro-cap biotech critique, but not an unfamiliar one for a stock up over 200% year-to-date.
Institutional flow adds another layer. Soleus Capital filed a fresh Schedule 13G in early August, disclosing a 4.6% passive stake built entirely in the current quarter. Tang Capital and Perceptive Advisors both initiated positions in Q2. BlackRock and Vanguard also added shares in July. That cluster of new institutional money arriving as the stock rallied is a notable demand signal, though the 13G designation for Soleus means the stake is disclosed as passive — not activist — and positions below 5% may exit without further disclosure. The top two holders, CEO Ron Bentsur and Charles Mosseri-Marlio, together control over 21% of shares, a concentrated insider register that limits effective float.
The next formal event is earnings on November 4. Prior prints have produced mixed reactions — a 10.8% single-day drop in August and a 6.3% gain in May — so the directional read from history is noisy. Between now and then, the stock's trajectory will depend on whether borrow continues to loosen or tightens again as the pipeline calendar approaches, and whether peers like VTGN and UNCY — both down on the week — exert any drag on the small-cap biotech cohort.
See the live data behind this article on ORTEX.
Open NVCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
